Mapping the translational science policy ‘valley of death’

Clinical and Translational Medicine - Tập 2 Số 1 - 2013
Eric M. Meslin1,2, Alessandro Blasimme2, Anne Cambon‐Thomsen2
1Indiana University Center for Bioethics, 410 West 10th Street, 46202 Indianapolis, USA
2UMR 1027, Inserm Université Toulouse III ‐ Paul Sabatier 31000 Toulouse France

Tóm tắt

AbstractTranslating the knowledge from biomedical science into clinical applications that help patients has been compared to crossing a valley of death because of the many issues that separate the bench from the bedside and threaten to stall progress. But translation is also inhibited by a science policy environment with its own impediments. Mapping these policy impediments give a more complete picture of the valley of death. Stem cell science is one example where success in moving from the bench to the bedside has confronted policy challenges generating difficulties as challenging as those facing scientists and clinicians. We highlight some of the characteristics and challenges of the science policy valley of death common to the U.S. and Europe, illustrate them with a recent example from stem cell science, and describe some promising strategies for traversing the valley.

Từ khóa


Tài liệu tham khảo

10.1126/scitranslmed.3002747

European Science Foundation: Science in Society:a Challenging Frontier for Science Policy.http://www.esf.org/fileadmin/Public_documents/Publications/Science_in_Society_04.pdf.

Government of Canada CIHR:Strategy for Patient‐Oriented Research. [http://www.cihr‐irsc.gc.ca/e/41204.html].

10.1097/GIM.0b013e31815699d0

European Commission, 2012, Biobanks for Europe ‐ A Challenge for Governance

10.1111/j.1752-8062.2011.00366.x

10.1038/nrd3078

10.1056/NEJMp1006304

10.1126/scitranslmed.3000265

10.1111/j.1752-8062.2010.00248.x

Association of Independent Research Institutes (AIRI):Translational Research Success Stories form AIRI Member Institutes. [http://www.airi.org/membership/translational.pdf].

10.1038/embor.2008.237

Carlson J, 2011, Divisiveness brings uncertainty. Stem‐cell researchers look elsewhere for funding, Mod Healthc, 41, 8

FDA:Innovation or Stagnation Challenge and Opportunity on the Critical Path to New Medical Products.http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm.

10.1001/jama.2007.26

Latour B, 1987, Science in Action: How to Follow Scientists and Engineers Through Society

Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs; Board on Population Health and Public Health Practice, Institute of Medicine, 2012, Ethical and Scientific Issues in Studying the Safety of Approved Drugs

10.1016/j.stem.2011.01.002

OECD:OECD Science Technology and Industry Outlook.http://www.oecd.org/sti/oecdsciencetechnologyandindustryoutlook.htm.

TachibanaM AmatoP SparmanM GutierrezNM Tippner‐HedgesR et al.:Human Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer.http://www.cell.com/abstract/S0092–8674(13)00571–0.

10.1126/science.282.5391.1145

WadeN:Researchers Claim Embryonic Cell Mix of Human and Cow ‐ New York Times.http://www.nytimes.com/1998/11/12/us/researchers‐claim‐embryonic‐cell‐mix‐of‐human‐and‐cow.html?pagewanted=all&src=pm.

Hong S, 2008, The Hwang scandal that «shook the world of science», East Asian Sci Technol Soc Int J, 2, 1, 10.1215/s12280-008-9041-x

10.1016/j.cell.2007.11.019

10.1353/ken.2002.0005

10.1057/9780230594364

Caulfield T, 2009, The stem cell research environment: a patchwork of patchworks, Stem Cell Rev, 5, 82, 10.1007/s12015-009-9071-3

10.1016/j.stem.2008.11.009

DeFrancesco L, 2012, FDA prevails in stem cell trial, Nat Biotechnol, 30, 906, 10.1038/nbt1012-906b

Tribunale di Venezia – Sezione Lavoro:Proc. Ex Art. 700 CPC ante causam Carrer Celeste c/Spedali Civili di Brescia. August 7 2012. N.1817/2012 RG.

Telethon:La scienza non si improvvisa.http://www.corriere.it/salute/13_marzo_07/telethon‐lettera‐staminali_f74b40e2–870b‐11e2–82ae‐71d5d7252090.shtml.

Staminali lettera aperta al ministro della Sanità.http://www.associazionelucacoscioni.it/rassegnastampa/staminali‐lettera‐aperta‐al‐ministro‐della‐sanit.

ISSCR Press Releases and Statements.http://www.isscr.org/home/about‐us/news‐press‐releases/2013/2013/04/10/isscr‐voices‐concern‐as‐italian‐government‐authorizes‐unproven‐stem‐cell‐therapy.

Bush V, 1945, Science: The Endless Frontier

Fox DM, 2010, The Convergence of Science and Governance: Research, Health Policy, and American States, 10.1525/9780520946125

Newby DE, 2010, Translational research: a priority for health and wealth, Heart, 96, 815, 10.1136/hrt.2010.198077

10.1038/35011576

Nowotny H, 2001, Re‐Thinking Science: Knowledge and the Public in an Age of Uncertainty

European Science Foundation:, 2013, Science in Society: Caring for our future in turbulent times

Kaye J, 2012, ELSI 2.0 for genomics and society, 336, 673

10.1371/journal.pone.0031824

MartinBScience Policy Research: Having an Impact on Policy?.http://www.ohe.org/publications/article/science‐policy‐research‐having‐an‐impact‐on‐policy‐14.cfm.

CollinsF BeaudetA Draghia‐AkliR GrussP SavillJ et al.:A database on global health research in Africa.Lancet Glob Healhttps://doi.org/10.1016/S2214‐109X(13)70012‐3

Salter B, 2007, Global Politics of Human Embryonic Stem Cell Science, Glob Gov, 13, 277, 10.1163/19426720-01302009

10.1186/1744-8603-7-3

Salter B, 2010, Governing innovation in the biomedicine knowledge economy: stem cell science in the USA, Sci Public Policy, 37, 87, 10.3152/030234210X489617

10.1126/science.1224004

Dewey J, 1989, The Public and Its Problems

Blasimme A, 2013, Translating stem cells to the clinic: scientific societies and the making of regenerative medicine, Quaderni, 81, 29, 10.4000/quaderni.704

10.1111/j.1467-6478.2012.00573.x

Bohman J, 2006, Deliberative democracy and the epistemic benefits of diversity, Episteme, 3, 175, 10.3366/epi.2006.3.3.175

Thông tin
Thông tin xuất bản

Clinical and Translational Medicine

Tập 2 Số 1

Thông tin tác giả